A Pharmacokinetic Model of Topotecan Clearance from Plasma and Cerebrospinal Fluid

Cancer Research

Volumn 54, Issue 19, 1994, Pages 5118-5122

  Cole, Diane E ^c   Balis, Frank M ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYACID; LACTONE; TOPOTECAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; NONHUMAN; PLASMA; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CAMPTOTHECIN; HAPLORHINI; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; TOPOTECAN;

EID: 0027940704     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Rowinsky, E. K. Grochow, L. B. Hendricks, C. B. Ettinger, D. S. Forastiere, A. A. Hurowitz, L. A. McGuire, W. P. Sartorius, S. E. Lubcjko, B. G. Kaufmann, S. H. and Donehower, R. C. Phase I and pharmacologic study of topotecan: a novel topoisomerase inhibitor. J. Clin. Oncol. 10: 647-656, 1992.
2. Wall, J. G. Burns, H. A. Ill, Von Hoff, D. D. Rodriguez, G. Kneuper-Hall, R. Shaffer, D. O'Rourke, T. Brown, T. Weiss, G. Clark, G. McVea, S. Brown, J. Johnson, R. Friedman, C. Smith, B. Mann, W. S. and Kuhn, J. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs, 3: 337-345, 1992.
3. Houghton, P. J. Cheshire, P. J. Myers, L. Stewart, C. F. Synold, T. W. and Houghton, J. A. Evaluation of 9-dimethyl aminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol. 31: 229-239, 1992.
4. Kantarjian, H. M. Beran, M. Ellis, A. Zwelling, L. O'Brien, S. Cazenave, L. Koller, C. Rios, M. B. Plunkett, W. Keating, M. J. and Estey, E. H. Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed acute leukemia. Blood, 81: 1146-1151, 1993.
5. Blaney, S. M. Balis, F. M. Cole, D. E. Craig, C. Reid, J. M. Ames, M. M. Krailo, M. Reaman, G. Hammond, D. and Poplack, D. G. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-h continuous infusion. Cancer Res. 53: 1032-1036, 1993.
6. Priel, E. Showalter, S. D. and Blair, D. G. Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoi-somerase I inhibitor. AIDS Res. Hum. Retroviruses, 7: 65-72, 1991.
7. Li, C. J. Zhang, L. J. Dezube, B. J. Crumpacker, C. S. and Pardee, A. B. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc. Natl. Acad. Sei. USA, 90: 1839-1842, 1993.
8. Priel, E. Aflalo, E. Chechelnitsky, G. Benharroch, D. Aboud, M. and Segal, S. Inhibition of retrovims-induced disease in mice by camptothecin. J. Virol. 67: 3624-9, 1993.
9. Underberg, W. J. M. Goossen, R. M. J. Smith, B. R. and Beijnen, J. H. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J. Pharm. Biomed. Anal. 8: 681-683, 1990.
10. McCully, C, Balis, F. Bacher, J. Phillips, J. and Poplack, D. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab. Anim. Sci. 40: 520-525, 1990.
11. Blaney, S. M. Cole, D. E. Balis, F. M. Godwin, K. and Poplack, D. G. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res. 53: 725-727, 1993.
12. Curran, R. Mosher, M. Owens, E. and Fenstermacher, J. Cerebrospinal fluid production rates determined by simultaneous albumin and inulin perfusion. Exp. Neurol. 29: 546-553, 1970.
13. Forsyth, R. Nies, A. Wyler, F. Neutze, J. and Melmon, K. Normal distribution of cardiac output in the unanesthetized, restrained rhesus monkey. J. Appl. Physiol. 25: 736-741, 1968.
14. Crone, C. and Christensen, O. Cardiovascular physiology III. In: A. Guyton and D. Young (ed.), Internal Review Physiology, pp. 149-213. Baltimore: University Park Press, 1979.
15. Calder, W. A. Ill, and Braun, E. J. Scaling of osmotic regulation in mammals and birds. Am. J. Physiol. 244: R601-R606, 1983.
16. Grochow, L. B. Rowinsky, E. K. Johnson, R. Ludeman, S. Kaufmann, S. H. McCabe, F. L. Smith, B. R. Hurowitz, L. DeLisa, A. Donehower, R. G. and Noe, D. A. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metabo. and Dispos. 20: 706-713, 1992.
17. Slichenmyer, W. Rowinsky, E. Donehower, R. and Kaufmann, S. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85: 271-291, 1993.